Decipher Biosciences focuses on advancing personalized treatment for urologic cancers, specifically prostate and bladder cancers, through its genomic testing technologies. The Decipher Prostate test is a tissue-based genomic assay that provides critical insights for treatment decision-making in localized prostate cancer. It is recognized as the most validated tissue-based gene expression test in this field, offering actionable information that helps physicians and patients navigate the complexities of cancer care. This test has been shown to have prognostic value, particularly for patients undergoing active surveillance, and has received high ratings in evidence-level assessments among molecular tests.

In addition to the prostate test, Decipher Bladder serves as a unique genomic subtyping tool for bladder cancer patients, aiding in informed treatment decisions. This tool is the only commercially available option of its kind, emphasizing the company's commitment to providing evidence-driven solutions for cancer management. Both Decipher tests are part of Veracyte's CLIA-validated laboratory developed test (LDT) service, underscoring their reliability and clinical relevance in the ongoing effort to personalize cancer treatment and improve patient outcomes.

Canada

Decipher Biosciences, formerly GenomeDx, is a genomic information company headquartered in Vancouver, British Columbia, with laboratories in San Diego, California.

Decipher Biosciences

Company Details